• Careers
  • Investors
  • News
  • Partnering
  • Contact Us
 
  • Home
  • Our Products
    • Recent Products
    • Consumer Products
    • Medical Devices & Diagnostics
    • Prescription Products
    • Product Coupons
  • Our Caring
    • Our Stories
    • Our Giving
    • Our Responsibility
    • Protecting Our People
    • Company Initiatives
  • Our Company
    • Our Credo Values
    • Our Management Approach
    • Our Citizenship
    • Corporate Governance
    • Company Structure
    • Our People & Diversity
    • Company Publications
    • Our History
  • News
    • All News
    • Corporate News
    • Product And Operating Company News
    • Financial News
    • Media Contacts
    • All News Archive
  • Text Size
  • Text Only
  • Email to a Friend
  • Printer Friendly
  • RSS

All News

Find press releases issued in the past two years issued by Johnson & Johnson corporate headquarters and our operating companies.

< Prev | | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | .... 39 Next >
New Phase 3 Data Show SIMPONI® Intravenous Formulation Significantly Improved Rheumatoid Arthritis Signs And Symptoms In Patients With Active Disease

June 05, 2012

Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes

June 05, 2012

ZYTIGA® Plus Prednisone Show Improvements in Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer

June 02, 2012

ASP Features Education And Innovation In The Fight Against Infection At APIC’s 39th Annual Educational Conference

May 31, 2012

Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes

May 31, 2012

FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet

May 29, 2012

< Prev | | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | .... 39 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Employees
  • Careers
  • Investors
  • News
  • Partnering
  • Contact Us
Johnson & Johnson
  • Home
  • Our Products
  • Our Caring
  • Our Company
  • All News
  • Corporate News
  • Product And Operating Company News
  • Financial News
  • Media Contacts
  • All News Archive
  • Text Size
  • Graphic Version
  • Email to a Friend
  • Printer Friendly
  • RSS

All News

Find press releases issued in the past two years issued by Johnson & Johnson corporate headquarters and our operating companies.

< Prev | | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | .... 39 Next >
New Phase 3 Data Show SIMPONI® Intravenous Formulation Significantly Improved Rheumatoid Arthritis Signs And Symptoms In Patients With Active Disease

June 05, 2012

Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes

June 05, 2012

ZYTIGA® Plus Prednisone Show Improvements in Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer

June 02, 2012

ASP Features Education And Innovation In The Fight Against Infection At APIC’s 39th Annual Educational Conference

May 31, 2012

Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes

May 31, 2012

FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet

May 29, 2012

< Prev | | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | .... 39 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •